person · Reporting owner
Struthers Richard Scott
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Frazier Life Sciences Acquisition Corp. IIFLSC · Entity 184069 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Frazier Life Sciences Acquisition Corp. II
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 12
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 248,043 · Balance 176,663 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 12 · 2026-09-01 · Disposition to issuer · Disposed 176,663 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Disposition to issuer · Disposed 1,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 1 | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 136,805 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 2 | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 106,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 3 | 0 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Disposition to issuer · Disposed 110,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 4 | 0 |
Reported balance
After 2026-09-01 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-09-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 5 | 0 |
Reported balance
After 2026-09-01 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 6 | 0 |
Reported balance
After 2026-09-01 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 7 | 0 |
Reported balance
After 2026-09-01 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust 8 | 0 |
Reported balance
After 2026-09-01 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2026-09-01 · Disposition to issuer · Disposed 111,100 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy Charitable Trust | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2026-09-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.19 · Expires 2029-03-08 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Disposition to issuer · Disposed 172,281 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.61 · Expires 2030-02-24 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-01 · Disposition to issuer · Disposed 195,578 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.29 · Expires 2031-02-26 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-01 · Disposition to issuer · Disposed 259,058 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.02 · Expires 2032-02-29 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-01 · Disposition to issuer · Disposed 244,205 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-09-01 · Disposition to issuer · Disposed 287,700 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.51 · Expires 2034-03-03 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-09-01 · Disposition to issuer · Disposed 240,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.86 · Expires 2035-02-19 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-09-01 · Disposition to issuer · Disposed 313,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-09-01 · Disposition to issuer · Disposed 228,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 3, 2022 02:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 53,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015134 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,400 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2023.. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 6 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 4 Disclosed balance after: 90,000 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 5 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 3 Disclosed balance after: 90,000 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:00 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-055312 · doc4.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 2 Disclosed balance after: 90,000 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:21 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 294,000 | $0.00 Strike: $15.29 | $0.00 |
DisclosureSEC source: 0001209191-21-016245 · doc4.xml · derivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,000 Underlying: Common Stock · 294,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:59 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | PurchaseCommon stock | 4,000 | $13.10 | $52,400.00 |
DisclosureSEC source: 0001209191-20-061822 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:59 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | PurchaseCommon stock | 1,000 | $12.60 | $12,600.00 |
DisclosureSEC source: 0001209191-20-061822 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,000 Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 17,500 | $14.46 | $253,107.75 |
DisclosureSEC source: 0001209191-20-042897 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 890,805 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.10 and $15.34 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 21:05 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon stock | 17,500 | $15.30 | $267,722.00 |
DisclosureSEC source: 0001209191-20-042897 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 908,305 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.95 and $15.76 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:12 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $22.61 | $0.00 |
DisclosureSEC source: 0001209191-20-012974 · doc4.xml · derivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-23 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020. Read SEC document |
| August 13, 2019 Filed Feb 11, 2020 21:09 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008280 · doc5.xml · nonDerivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 4 Disclosed balance after: 100,000 Read SEC document |
| August 13, 2019 Filed Feb 11, 2020 21:09 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008280 · doc5.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 3 Disclosed balance after: 100,000 Read SEC document |
| August 13, 2019 Filed Feb 11, 2020 21:09 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008280 · doc5.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 2 Disclosed balance after: 100,000 Read SEC document |
| August 13, 2019 Filed Feb 11, 2020 21:09 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008280 · doc5.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust 1 Disclosed balance after: 925,805 Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 23:31 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001209191-19-045039 · doc4.xml · derivative · entry 4 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,370 Underlying: Common Stock · 10,000 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 23:31 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Exercise / conversionCommon Stock | 10,000 | $1.91 | $19,100.00 |
DisclosureSEC source: 0001209191-19-045039 · doc4.xml · nonDerivative · entry 3 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 1,225,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2019 Filed Aug 7, 2019 23:31 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 1,215,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045039 · doc4.xml · nonDerivative · entry 2 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 1,215,805 F1 · kind: Reflects a transfer on May 8, 2019 of 1,215,805 shares by the Reporting Person to the Struthers Family Trust, of which the Reporting Person is the trustee. F1 · balance_after: Reflects a transfer on May 8, 2019 of 1,215,805 shares by the Reporting Person to the Struthers Family Trust, of which the Reporting Person is the trustee. Read SEC document |
| May 08, 2019 Filed Aug 7, 2019 23:31 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GiftCommon Stock | 1,215,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045039 · doc4.xml · nonDerivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects a transfer on May 8, 2019 of 1,215,805 shares by the Reporting Person to the Struthers Family Trust, of which the Reporting Person is the trustee. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 22:44 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (right to buy) · Derivative | 176,250 | $0.00 Strike: $25.19 | $0.00 |
DisclosureSEC source: 0001209191-19-018984 · doc4.xml · derivative · entry 1 Struthers Richard Scott · CIK 0001746298 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,250 Underlying: Common Stock · 176,250 shares Expires 2029-03-07 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the Vesting Commencement Date of March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.